Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Disney

Village Super Market

These investments will help you diversify while giving you a good mix of dividends, growth, and stability.

3 Stocks to Build Your Portfolio Around

Sanofi

Regeneron (REGN) and Sanofi's (SNY) Libtayo gets positive CHMP opinion for two additional indications.

Regeneron (REGN)-Sanofi's Libtayo Gets Positive CHMP Opinion

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Libtayo (cemiplimab) as monotherapy in two advanced cancers. The CHMP recommended the approval of Libtayo for the first-line treatment of adults with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥50% of tumor cells with no EGFR, ALK, or ROS1 aberrations.

Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings

TARRYTOWN, N.Y. and PARIS, May 24, 2021 /PRNewswire/ -- Libtayo recommended for approval in the first-line treatment of certain patients with advanced non-small cell lung cancer whose tumors have ≥50% PD-L1 expression Libtayo also recommended for approval in patients with advanced basal cell carcinoma who have progressed on or are intolerant to a hedgehog pathway inhibitor CHMP has now issued three positive opinions for Libtayo in advanced cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Libtayo® (cemiplimab) as monotherapy in two advanced cancers.

Libtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers

TARRYTOWN, N.Y. and WASHINGTON, May 21, 2021 /PRNewswire/ -- $75,000 Top Award Goes to 16-year-old Michelle Hua for Novel Human Action Recognition Algorithm in Regeneron International Science and Engineering Fair 2021 Regeneron Pharmaceuticals, Inc.  (NASDAQ: REGN) and Society for Science  (the Society) announced that Michelle Hua, 16, of Troy, Michigan, won the $75,000 top award in the 2021 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest global high school competition.

Teen Scientists and Engineers Win $5 Million at Largest Global High School STEM Competition

Ovid Therapeutics

Repligen

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

Regeneron achieved three FDA approvals in February 2021 and continued to announce positive clinical results in the following months, but the shares have since traded roughly sideways. Regeneron is conducting one of the largest genetic sequencing efforts in the world, positioning the company as a leader in the field now and in the future.

Regeneron: Priced For Value, Poised For Growth

TARRYTOWN, N.Y., May 19, 2021 /PRNewswire/ --  Presentations include first positive clinical data for the fianlimab (LAG-3 inhibitor) and Libtayo combination in advanced melanoma Regeneron will host an investor webcast on Monday, June 7 to provide further updates across its oncology portfolio Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the company will share a range of presentations for its PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and broader oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, taking place virtually.

Libtayo® (cemiplimab-rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse Cancers

Regeneron (REGN) resumes enrollment in two patient cohorts of pipeline candidate, odronextamab, a CD20xCD3 bispecific antibody, after the FDA lifts partial clinical hold.

Regeneron (REGN) Resumes Enrollment in Lymphoma Cohorts

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at RBC Capital Markets Virtual Global Healthcare Conference Call - (Transcript)

Weis Markets

Stocks that soar or plunge get all the attention.

Regeneron and Weis Markets Head Up the Do Nothing Club

TARRYTOWN, N.Y., May 17, 2021 /PRNewswire/ --  Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo Similar efficacy observed with both doses (1,200 mg and 2,400 mg); U.S. FDA is currently reviewing request to add lower 1,200 mg dose to EUA Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of detailed results from the Phase 3 pivotal trial showing REGEN–COV™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death, shortened symptom duration and reduced viral load in non-hospitalized patients (outpatients) with COVID-19.

Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients

TARRYTOWN, N.Y. and PARIS, May 17, 2021 /PRNewswire/ --  Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patients FDA decision for children with moderate-to-severe asthma expected by October 21, 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that detailed results from a Phase 3 trial showed Dupixent® (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, with evidence of type 2 inflammation.

Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children

TARRYTOWN, N.Y. and PARIS, May 12, 2021 /PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy Improvements in overall survival were seen in the overall population and both squamous cell carcinoma and adenocarcinoma subgroups Additionally, the Phase 3 trial found significant differences in patient-reported outcomes favoring Libtayo over chemotherapy Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive results from the Phase 3 trial investigating the PD-1 inhibitor Libtayo® (cemiplimab) in patients with recurrent or metastatic cervical cancer who had previously progressed on chemotherapy.

Positive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary

Regeneron stock inched higher Thursday after the biotech company's Covid-19 antibody treatment delivered a narrow first-quarter beat. Overall, sales were in line and earnings beat.

Regeneron Pops After Covid Treatment Beats First-Quarter Views

Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q1 2021 Results - Earnings Call Transcript

Regeneron (REGN) beats on Q1 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.

Regeneron (REGN) Q1 Earnings Beat on Strong Eylea & Dupixent

The big biotech delivered impressive revenue and earnings growth.

Why Regeneron's Q1 Results Looked Great Despite Its Revenue Miss

The shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are rising on the company's upbeat first-quarter earnings report, which boasted a rise in profits to $9.89 per share -- toppling analysts' estimates.

REGN Finds Redemption After Impressive Earnings Report

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed analyst consensus of $2.56 billion.

Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue

Regeneron (REGN) delivered earnings and revenue surprises of 12.51% and -1.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) Tops Q1 Earnings Estimates

Shares of Regeneron Pharmaceuticals Inc. rose 0.8% in premarket trading Thursday, after the biotechnology company beat first-quarter profit and revenue expectations, with sales of its REGEN-COV antibody cocktail to the SARS-CoV-2 virus also topping forecasts. Net income rose to $1.12 billion, or $10.09 a share, from $625 million, or $5.43 a share, in the year-ago period.

Regeneron stock rises, as profit, revenue and sales of SARS-CoV-2 antibody cocktail beat expectations

Regeneron Pharmaceuticals Inc reported a 78% rise in first-quarter profit on Thursday, helped by a robust recovery in demand for its eye drug Eylea.

Regeneron quarterly profit rises 78% on Eylea strength

TARRYTOWN, N.Y., May 6, 2021 /PRNewswire/ -- First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COV TM(1) increased 20% First quarter 2021 EYLEA® U.S. net sales increased 15% to $1.35 billion versus first quarter 2020 First quarter 2021 Dupixent® global net sales (2) , which are recorded by Sanofi, increased 48% to $1.26 billion versus first quarter 2020 First quarter 2021 GAAP diluted EPS was $10.09 and non-GAAP diluted EPS (1) was $9.89 Three FDA approvals received: Libtayo® for first-line advanced non-small cell lung cancer (NSCLC) and advanced basal cell carcinoma (BCC), and Evkeeza TM for homozygous familial hypercholesterolemia (HoFH) Positive data reported from Phase 3 trials with REGEN-COV used to treat and prevent COVID-19 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2021 and provided a business update.

Regeneron Reports First Quarter 2021 Financial and Operating Results

Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for Regeneron Pharmaceuticals Stock (REGN)